Marc Hellerstein

Research Expertise and Interest

plant biology, health and nutrition

In the News

For an effective COVID vaccine, look beyond antibodies to T-cells

More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at “warp speed” — possibly by the end of the year — but the bar set for an effective, long-lasting vaccine is far too low and may prove dangerous, according to Marc Hellerstein of the University of California, Berkeley.

Teaching

Courses taught during the three most recent semesters
2026 Spring 2025 Fall 2025 Spring